Tazarotene-induced gene 1 (TIG1) is a retinoic acid-inducible protein that is considered a putative tumor suppressor. The expression of TIG1 is decreased in malignant prostate carcinoma or poorly differentiated colorectal adenocarcinoma, but TIG1 is present in benign or well-differentiated tumors. Ectopic TIG1 expression led to suppression of growth in cancer cells. However, the function of TIG1 in cell differentiation is still unknown. Using a yeast two-hybrid system, we found that transmembrane protein 192 (TMEM192) interacted with TIG1. We also found that both TIG1A and TIG1B isoforms interacted and co-localized with TMEM192 in HtTA cervical cancer cells. The expression of TIG1 induced the expression of autophagy-related proteins, including Beclin-1 and LC-3B. The silencing of TMEM192 reduced the TIG1-mediated upregulation of autophagic activity. Furthermore, silencing of either TIG1 or TMEM192 led to alleviation of the upregulation of autophagy induced by all-trans retinoic acid. Our results demonstrate that the expression of TIG1 leads to cell autophagy through TMEM192. Our study also suggests that TIG1 and TMEM192 play an important role in the all-trans retinoic acid-mediated upregulation of autophagic activity.
Tazarotene-induced gene 1 (TIG1), also known as retinoic acid receptor responder 1 (RARRES1), was first identified in skin raft cultures treated with the RAR β/γ-selective retinoid AGN 190168, which is also called tazarotene (Nagpal et al., 1996). The TIG1 gene, which is located on chromosome 3q25.32, encodes two isoforms: TIG1A and TIG1B. These two isoforms are encoded by a 1.55-kb mRNA [GenBank: NM_206963] and an 883-bp mRNA [GenBank: NM_002888], which can be translated into proteins consisting of 294 amino acids with a molecular weight of 33.3 kDa or 228 amino acids with a molecular weight of 25.8 kDa, respectively.
TIG1 is structurally similar to the protein latexin with an N-terminal transmembrane domain ranging from 21 to 42 amino acids that targets the protein to endomembranes (Liang et al., 2007). Although latexin is considered a carboxypeptidase inhibitor, TIG1’s proteolytic activity remains unknown. TIG1 suppressed the growth and invasion of several types of cancer cells, and CpG hypermethylation of the TIG1 promoter led to downregulation of TIG1 expression in various carcinomas (Chen et al., 2014; Jing et al., 2002; Kwok et al., 2009; Kwong et al., 2005; Mizuiri et al., 2005; Peng et al., 2012; Shutoh et al., 2005; Wu et al., 2006; Yanatatsaneejit et al., 2008; Zhang et al., 2004). Expression of TIG1 is decreased in malignant prostate carcinoma cell lines and in poorly differentiated colorectal adenocarcinoma, but TIG1 is present in benign or well-differentiated tumor lines (Jing et al., 2002; Wu et al., 2006), and ectopic TIG1 expression led to suppression of growth in cancer cells (Jing et al., 2002; Tsai et al., 2011; Wu et al., 2011). Therefore, TIG1 might play an important role in retinoic acid-mediated cellular differentiation and tumor growth suppression.
The transmembrane protein 192 (TMEM192) gene is located on chromosome 4q32.3 and encodes a protein with 271 amino acids and a molecular weight of 30.9 kDa. TMEM192 is a lysosomal membrane-bound protein that is widely expressed in human kidney, liver, lung, and pancreas tissue (Schroder et al., 2010). Deficiency of TMEM192 in hepatoma HepG2 cells results in growth inhibition and increased apoptosis. Increased apoptosis in TMEM192-deficient cells was inhibited by blocking the autophagy gene Atg7, suggesting that TMEM192 plays an important role in autophagy and may contribute to the regulation of cell apoptosis (Liu et al., 2012).
Autophagy is a conserved lysosomal degradation pathway that controls the quality of the cytoplasm by destroying disassembled proteins and unnecessary or dysfunctional cellular components (Kobayashi, 2015; Lee et al., 2012; Mizushima and Komatsu, 2011). Autophagy is regulated by autophagy-related (Atg) genes that control the formation and maturation of double-membrane vesicles called autophagosomes, which engulf and transport cellular proteins and organelles. Autophagosomes subsequently fuse with lysosomes to form autolysosomes and then digest the contents with acid hydrolases provided by the lysosome (Lamb et al., 2013; Mizushima et al., 2011). Many Atg genes are involved in autophagosome formation, including the well-known Atg12-Atg5 and Atg8 (microtubule-associated protein 1 light chain 3, LC3)-phosphatidyle-thanolamine systems (Dooley et al., 2014; Hanada et al., 2007). ULK (the mammalian homolog of Atg1) and Beclin-1 (mammalian homolog of Atg6) have been shown to contribute to the activation of downstream autophagy components (Hara et al., 2008; Kang et al., 2011; Russell et al., 2013).
To ascertain the biological functions of TIG1, we screened novel interacting proteins of TIG1B using a yeast two-hybrid system. Our results showed that TIG1B directly binds to TMEM192. TIG1A shares the N-terminal 224 amino acids with TIG1B, suggesting that TIG1A may also interact with TMEM192. TMEM192 is considered a lysosomal protein that is involved in the autophagic process. In this study, we demonstrated a role for TIG1 in the induction of autophagy activity in cervical cancer cells via the TMEM192 protein.
Plasmids pAS2-1 and pACT2 and yeast strains Y187 and CG-1945 were purchased from Clontech Laboratories (USA). To generate an expression vector for the DNA-binding domain of the transcriptional activator GAL4 (GAL4 BD)-tagged cytoplasmic region of TIG1B, truncated TIG1B cDNA fragments were amplified from pTIG1B-myc using 5′ (5′-CCGAATTCCCCGAC GACCCTGGGCAGCC-3′) and 3′ (5′-ACGGATCCTCAGGTT TTTCTTACCCACTGCCTCACAC-3′) primers and then subcloned in-frame into the
The vector pEGFP-LC3 (human) was a gift from Toren Finkel (Addgene plasmid # 24920) (Lee et al., 2008). The vectors pTIG1A-myc and pTIG1B-myc have been described previously (Wu et al., 2011). To generate pTMEM192-Flag, the TMEM192 cDNA fragment was amplified from pTMEM192/PACT2 using 5′ (5′-TGGCTAGCATGGCGGCGGGGGGCAGGATG-3′) and 3′ (5′-CGGAATTCGCGTTCTACTTGGCTGACAGCCC-3′) primers and then subcloned in-frame into the
HeLa Tet-off (HtTA) cervical cancer cells were maintained in RPMI-1640 medium supplemented with 25 mM HEPES, 26 mM NaHCO3, 2 mM L-glutamine, penicillin (100 units/mL), streptomycin (100 μg/ml), and 10% fetal bovine serum (FBS) at 37°C in 5% CO2. The hepatoma-derived cell line Huh7 was a generous gift from Dr. C.-S. Hsu (Department of Internal Medicine, Taipei Tzuchi Hospital, The Buddhist Tzuchi Medical Foundation, Taiwan). Cells were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS, 2 mM L-glutamine, 100 units/ml penicillin, and 10 μg/ml streptomycin at 37°C under 5% CO2 in a 95% humidified atmosphere. Cells plated in culture dishes were transfected with the expression vectors using liposome-mediated transfection. Briefly, plasmids and Lipofectamine 2000 (Gibco BRL, USA) were diluted in Opti-MEM medium and then mixed with plasmids at room temperature for 15 min. The DNA-Lipofectamine complexes were then added to cells for 5 h at 37°C. Cells were refreshed with complete medium for 24–48 h at 37°C for further analysis.
Cells were lysed in modified RIPA buffer (20 mM Tris [pH 7.5], 100 mM NaCl, 1% NP-40, 30 mM sodium pyrophosphate) containing a protease inhibitor cocktail (Roche Diagnostics, Germany) and phosphatase inhibitors. Cell lysates containing 500 μg of protein were first incubated for 2 h at 4°C with 3.2 μg of anti-MYC (Invitrogen, USA) or anti-FLAG (Sigma, USA) monoclonal antibody and then incubated for 2 h at 4°C with 20 μl of protein G plus/protein A-agarose (Calbiochem, USA). Immunoprecipitated complexes were analyzed by Western blotting using an anti-FLAG or anti-MYC antibody after the complexes were washed three times with PBS. Alternatively, cell lysates containing 5 mg of protein were incubated first with 8 μg of normal mouse IgG (Santa Cruz Biotechnology, USA) or 8 μg of anti-TIG1 (Santa Cruz Biotechnology) antibody for 12 h at 4°C and then incubated with 20 μl of protein G plus/protein A agarose at 4°C for 2 h. Immunoprecipitated complexes were washed three times with modified RIPA buffer and then analyzed by Western blotting using anti-TMEM192 (Santa Cruz Biotechnology) antibody. For Western blotting, 20–60 μg of proteins was separated on 15% polyacrylamide gels and transferred to polyvinylidene fluoride membranes. After the membranes were blocked, they were incubated for 12 h at 4°C with anti-MYC, anti-FLAG, anti-TIG1 (Santa Cruz Biotechnology), anti-TMEM192 (Santa Cruz Biotechnology), anti-LC3B (Cell Signaling Technology, USA), anti-SQSTM1/p62 (Cell Signaling Technology), anti-Beclin-1 (Cell Signaling Technology), or antiactin (Sigma) antibody and then incubated with horseradish peroxidase-conjugated goat anti-mouse antibody at room temperature for 1 h. An ECL kit (Amersham, UK) was used to detect the substrate reaction.
HtTA and Huh7 cells (1 × 105) were plated on poly-L-lysine-coated coverslips in 35-mm dishes in growth medium. Cells were then transfected with 500 ng of TIG1A-myc or TIG1B-myc expression vector along with 500 ng pEGFP-TMEM192 expression vector for 18 h. The cells were washed, fixed with 4% paraformaldehyde and then incubated with anti-MYC antibody and anti-LAMP1 (lysosome-associated membrane protein 1) antibody (Cell Signaling Technology) followed by Alexa Fluor 633 anti-mouse IgG and Alexa Fluor 405 anti-rabbit IgG antibodies (Invitrogen). The cells were then analyzed for TIG1A or TIG1B and EGFP-TMEM192 expression with a Leica TCS SP5 scanner (Leica, Germany). Alternatively, cells were plated in triplicate in 24-well plates at a density of 2 × 104 cells per well in RPMI-1640 medium containing 10% FBS and incubated overnight. The cells were transfected with 75 ng of TIG1A-myc or TIG1B-myc expression vector or with 75 ng of TMEM192-Flag expression vector along with 150 ng of pGFP-LC3 expression vector and then refreshed with complete medium immediately and 24 h after transfection. Cells were refreshed in medium without serum and treated with 400 nM rapamycin for 6 h. The cells were washed, fixed with 4% paraformaldehyde and then analyzed with an Olympus IX-70 immunofluorescence microscope (Olympus, Denmark). The percentage of cells with GFP-LC3 puncta formation was calculated by counting the number of cells with punctate GFP-LC3 fluorescence of all GFP-positive cells. A minimum of 100 cells from 3 randomly selected fields were scored.
Total RNA was extracted using TRIZOL reagent (Invitrogen) according to the manufacturer’s instructions. The total RNA was then reverse transcribed to cDNA by incubating at 37°C for 1 h in 20 μl of a mixture containing 3 μg total RNA, 1 U Moloney murine leukemia virus (MuLV) reverse transcriptase (Invitrogen), 0.5 μg oligo-dT12–18, 4 μl 5X RT buffer, 0.5 mM dNTP, and 1 U RNaseout recombinant RNase inhibitor. Quantitative real-time PCR (Q-PCR) was performed in triplicate using 20 μl of the reaction mixture containing 10 μl Fast SYBR Green Master Mix (Applied Biosystems, USA), 50 ng cDNA, and gene-specific forward and reverse primers at 1 μM final concentration in a thermal cycler (7900HT Fast Real-Time PCR System, ABI). The PCR cycling had an initial incubation at 95°C temperature for 3 min, 40 cycles of denaturation at 95°C for 15 s followed by annealing and extension at 60°C for 1 min. The PCR primers used for amplification included the following: GAPDH (sense, 5′-GAGTCAACGGATTTGGTCGT-3′ and antisense, 5′-TTGAT TTTGGAGGGATCTCG-3′), TIG1 (sense, 5′-CGTGGTCTTCA GCACAGAGCG-3′ and antisense, 5′-CCCAAACGTCCCTCAC CTTCC-3′), and TMEM192 (sense, 5′-CAGTCCTCTGGCAAC ACAGT-3′ and antisense, 5′-CTGAATCCAGTCTCCGAGGT-3′). The relative expression levels of the TIG1 and TMEM192 cDNA were quantified after normalizing for GAPDH.
Two TIG1 siRNAs, which are targeted to nucleotides 488–508 and 540–560 of both TIG1A and TIG1B, have been described previously (Wu et al., 2011). TMEM192 siRNA oligonucleotides were synthesized by Sigma. Two TMEM192 siRNAs targeted to nucleotides 441–459 (5′-CCAGUAUCACCACAGCAAAtt-3′) and 779–797 (5′-CUAUUUCAAGCCUAGAAGAtt-3′) were synthesized based on GenBank accession number NM_001100389.1. The universal control (NC) siRNA (Sigma) was used as a negative control.
HtTA and Huh7 cells were seeded at 1 × 105 cells per well in 6-well plates overnight and then transfected with pTIG1A-myc, pTIG1B-myc expression vector, or control vector for 5 h. Cells were refreshed with complete medium for 24 h and then incubated in medium without serum for 6 h. Alternatively, cells were transfected with TIG1 siRNA, TMEM192 siRNA, or NC siRNA for 5 h and then incubated in medium without serum for 6 h after which they were incubated in growth medium containing all-trans retinoic acid (ATRA) for 48 h. After the cells were washed twice with PBS, they were lysed with modified RIPA buffer, scraped, and collected by centrifugation. The levels of Beclin-1 in the supernatants were determined using a human Beclin-1 ELISA kit according to the manufacturer’s instructions (LSBio, Lifespan Biosciences Inc, USA).
Data are represented as the mean ± SD of at least duplicate studies. Statistical analyses were performed using one-way ANOVA with Dunnett’s post hoc test for comparisons of more than two groups. Student’s
We performed yeast two-hybrid screening using the cytoplasmic region of TIG1B as bait and found that TIG1B can interact with TMEM192. To confirm the interaction between TIG1 and TMEM192, we first constructed expression vectors that synthesized recombinant proteins containing Flag-tagged TMEM192. Ectopically expressed recombinant TMEM192-FLAG fusion protein with the expected molecular weight of 35 kDa was observed in HtTA cells after transient transfection for 24 h (Figs. 1A and 1B). We then performed co-immunoprecipitation using anti-MYC antibody against the MYC epitope of the TIG1A or TIG1B fusion proteins in lysates of TMEM192-Flag-transfected HtTA cells. The TIG1A and TIG1B proteins were detected on immunoblots from TMEM192 co-transfected immunoprecipitates, indicating the presence of TIG1A and TIG1B in the TMEM192 pull-down protein complexes prepared
To further verify the co-localization of TIG1 and TMEM192
Because TIG1 is considered a carboxypeptidase inhibitor (Aagaard et al., 2005), we then examined the effect of TIG1 on TMEM192 mRNA and protein expressions. Upon transfection of TIG1A-myc expression vector for 24 h, TIG1 mRNA level was increased by 4314-fold. Induced expression of TIG1A didn’t significantly increased TMEM192 mRNA levels (Fig. 2A). Similar result was observed in cells expressing TIG1B (data not shown). In addition, TMEM192 mRNA level was increased by 3220-fold in cells transfected with TMEM192-flag expression vector. The expression of TIG1mRNA did not differ between control and TMEM192-transfected cells (Fig. 2B). Transfection with 0.5–1.5 μg of TIG1A-myc (Fig. 2C) or TIG1B-myc (Fig. 2D) expression vectors did not considerably affect the expression of TMEM192 protein, suggesting that TIG1 did not affect the stability of the TMEM192 protein. Similarly, no significant alteration of TIG1A-MYC (Fig. 2E) or TIG1B-MYC (Fig. 2F) protein levels was observed in cells transfected with 0.5–1.5 μg of TMEM192-Flag expression vectors.
Since TMEM192 deficiency can induce autophagy (Liu et al., 2012), we next examined whether TIG1 plays an important role in the autophagy pathway. Two key proteins of autophagy, LC3B and Beclin-1, were examined to assess autophagic activity. Protein expression of LC3B-I and LC3B-II (autophagosome marker proteins) was determined by Western blot analysis, and the LC3B-II/LC3B-I ratios were positively correlated with the number of autophagosomes (Kadowaki and Karim, 2009). Upon autophagy induction with rapamycin, the LC3B-II/LC3B-I ratio increased significantly by 2.9–4.7-fold (Fig. 3A and
We further examined the effect of TIG1 on Beclin-1 production. The levels of Beclin-1 were increased by 1.72–2.26-folds in cells expressing TIG1A or TIG1B. In cells expressing TIG1A or TIG1B along with TMEM192 and treated with rapamycin, the levels of beclin-1 were increased by 2.1–7.6-folds (Fig. 3C and
Cells transfected to express GFP-LC3 showed autophagosome formation in response to rapamycin (Fig. 3E and
SQSTM1/p62 is an autophagy adaptor. The levels of SQSTM1/p62 decreased in cells treated with rapamycin but not in cells expressing TIG1A or TIG1B. This result suggests that TIG1 does not enhance cell autophagy through the SQSTM1/p62 protein (Fig. 3A,
To ascertain the role of TMEM192 in TIG1-mediated upregulation of autophagy, we examined the effects of TMEM192 silencing on the production of LC3B-II and Beclin-1 in TIG1-expressing cells. HtTA cells were transiently transfected with pTIG1-myc or pTMEM192-Flag expression vector along with siRNAs specific for TIG1 or TMEM192 for 48 h. No TIG1A or TIG1B protein was detected in TIG1A or TIG1B-expressing cells transfected with each TIG1 siRNA, while TMEM192 protein levels were reduced by 87% or were barely detectable in TMEM192-expressing cells transfected with each TMEM192 siRNA (Figs. 4A–4C).
Our results showed that the LC3B-II/LC3B-I ratios were markedly decreased by 66.2–68.2% or 52.6–66.5% in TIG1A-expressing cells co-transfected with either TIG1 or TMEM192 siRNAs compared with cells co-transfected with NC siRNA (Figs. 4C and 4D). Similarly, compared to TIG1B-expressing cells transfected with NC siRNA, TIG1 or TMEM192 siRNAs significantly decreased the LC3B-II/LC3B-I ratios by 77.8–80.5% or 51.7–74%, respectively (
To further confirm the enhanced ability of TIG1 to influence autophagy, we examined the effect of endogenous TIG1 on the production of LC3B and Beclin-1. TIG1B, but not TIG1A, could be detected in HtTA and Huh7 cells using TIG1 antibody (Fig. 5A and
TIG1 is a retinoid-inducible protein (Nagpal et al., 1996), and previous studies have confirmed that ATRA can induce the activation of autophagy in leukemia cells (Anguiano et al., 2013; Orfali et al., 2015; Rajawat et al., 2010). To determine whether TIG1 or TMEM192 contributes to the ATRA-mediated activation of autophagy, we examined the effects of TIG1 or TMEM192 silencing on the production of LC3B and Beclin-1 in ATRA-treated cells. As shown in Fig. 6A, TIG1 levels were increased in a dose-dependent manner, with a maximal 45% increase in cells treated with 10−6 M ATRA (Fig. 6A). Our results showed that the ratio of LC3B-II to LC3B-I and the production of Beclin-1 were markedly increased by 3.2-fold and 31.5–64.3%, respectively, in cells treated with 10−6 M ATRA (Figs. 6B, 6C, 6D, and 6E). The ratio of LC3B-II to LC3B-I and the production of Beclin-1 were decreased by 55.1–73.5% and 10.7–38.4%, respectively, in ATRA-treated HtTA cells that expressed either TIG1 or TMEM192 siRNAs compared with cells expressing NC siRNA (Figs. 6B, 6C, 6D, and 6E). No obvious change of TIG1 or TMEM192 protein levels was observed in cells transfected with TMEM192 or TIG1 siRNAs, respectively (Fig. 6B). The result confirms that expression of TIG1 or TMEM192 in HtTA cells did not appear to influence each other protein level observed in Fig. 2. Similar effects on LC3B and Beclin-1 were observed in ATRA-treated Huh7 cells transfected with TIG1 and TMEM192 siRNAs (
TIG1 is thought to be a retinoid-inducible tumor suppressor, and its mechanism of tumor suppression is largely unknown. Our previous studies showed that both isoforms of TIG1 suppressed cell growth and induced G protein-coupled receptor kinase 5 (GRK5) expression in colon cancer cells (Wu et al., 2011). We further explored the inhibitory effect of TIG1 on PGE2-induced cellular proliferation and signaling in colon cancer cells, which are processes that involve the downregulation of G protein-coupled signaling via the upregulation of GRK5 expression (Tsai et al., 2011). In addition to the upregulation of GRK5 by TIG1, we demonstrated here that TIG1 interacted with TMEM192 to induce autophagic activity in HtTA cervical cells and Huh7 hepatic cells.
Autophagy has been reported to be involved in cancer cell proliferation or tumorigenesis in a variety of ways (White, 2015). The Beclin-1 autophagy gene is monoallelically deleted in 40–75% of human sporadic breast, ovarian, and prostate cancer (Aita et al., 1999; Choi et al., 2013; Liang et al., 1999). Heterozygous disruption of Beclin-1 increases the frequency of liver and lung tumors and lymphomas in mice (Qu et al., 2003; Yue et al., 2003). Cancer cells also rely on autophagy. Autophagy is upregulated in RAS-transformed cancer cells and facilitates cancer growth and tumorigenesis (Guo et al., 2011; Lock et al., 2011; 2014). Mice with systemic mosaic deletion of Atg5 or Atg7 develop benign liver adenomas (Takamura et al., 2011). Autophagy has a critical role in pancreatic ductal adenocarcinoma pathogenesis (Yang et al., 2011). Therefore, autophagy promotes or inhibits tumor progression depending on the cell types and the microenvironment stimuli. The underlying mechanisms by which TIG1 induces autophagy are not completely clear at present. In addition to the target TMEM192 protein, the involvement of the TIG1/TMEM192 complex in autophagosome formation and activation of autophagy needs further investigation. Furthermore, the role of induced autophagic activity by TIG1 in cancer cell proliferation or tumorigenesis should also be determined.
Aside from its involvement in cancer development, autophagy plays a critical role in a variety of cell differentiation processes (Bernard et al., 2014; Simon, 2012; Vessoni et al., 2012; Zhuang et al., 2011). Autophagy regulates myeloid cell differentiation, and autophagy is increased during ATRA-induced granulocytic differentiation of acute promyelocytic leukemia cells (Orfali et al., 2015; Wang et al., 2011). How autophagy is induced by ATRA is not yet known, but our results revealed that silencing of either TIG1 or TMEM192 alleviated ATRA-upregulated autophagy. Whether the TIG1/TMEM192 pathway is involved in ATRA-mediated myeloid cell differentiation needs further investigation. Regardless of how the downstream signaling pathway of TIG1 is regulated, TMEM192 knockdown affects TIG1-mediated upregulation of autophagy.
Although TIG1-mediated autophagy depends on the expression of TMEM192 as indicated by the present study, it has also been shown that TMEM192 deficiency triggers autophagy in HepG2 hepatoma cells (Liu et al., 2012). Furthermore, based on caspase-12 activation, apoptosis was not observed in HtTA cervical cells in which TMEM192 was either overexpressed or silenced (data not shown). Difference in cell type might be the main cause of the different effects elicited by TMEM192 deficiency. Enhanced TMEM192 can only mediate TIG1 induction of autophagy-related proteins in rapamycin-treated TIG1-expressing cells but not in untreated TIG1-expressing cells (Fig. 3 and
Our present results demonstrate that only the TIG1B isoform was detected in HtTA and Huh7 cells, even though similar mRNA expression of TIG1A and TIG1B was observed (Wu et al., 2011). Similarly, previous studies analyzing the suppression of cell growth and invasion by TIG1 have focused on the TIG1B isoform (Jing et al., 2002; Kwok et al., 2009). Regardless of the different expression levels of TIG1A and TIG1B, both TIG1 isoforms exhibited similar autophagic activities in transiently transfected HtTA cervical cells. This result suggests that the induction of autophagic activities by the TIG1 protein may reside in the amino terminus region of the TIG1 protein, which is supported by co-localization and interaction of both of the TIG1 isoforms with TMEM192 and the identical effect of the TIG1 isoforms on TMEM192-mediated regulation of autophagy-related proteins. Further analysis of the correlation between TMEM192 and Atg activities will be important for elucidation of the autophagic function of the TIG1 proteins.
In conclusion, our present results demonstrate that TIG1 isoforms can interact with TMEM192. Expression of TIG1 led to autophagy, and silencing of TMEM192 resulted in decreased autophagic activity induced by TIG1. Furthermore, silencing of either TIG1 or TMEM192 expression decreased the ATRA-mediated upregulation of autophagy. Our results show that TIG1 is involved in ATRA-induced autophagic activity via the TMEM192 protein.